NCT01341522

Brief Summary

Permanent cardiac pacemakers have represented a contraindication to Magnetic Resonance Imaging (MRI). Strong static, gradient and radiofrequency fields used for MRI are thought to be detrimental to pacemaker function and possibly cause harm to patients undergoing MRI examinations. A previous study has shown that MRI is indicated in 17% of all patients with pacemakers within 12 months of device placement , which demonstrates the need of practical, safe approach for performing MRI on pacemaker patients. A new Reply MR-conditional pacing system is developed by Sorin Group for safe use in the MRI environment. The new pacing system is composed by the Reply pacemaker and the Filtrea bradycardia pacing leads. This study intends to demonstrate the safety and the efficacy in the MRI environment of the Sorin Group Reply MR-conditional pacing system.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jan 2012

Shorter than P25 for phase_3

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 1, 2011

Completed
24 days until next milestone

First Posted

Study publicly available on registry

April 25, 2011

Completed
8 months until next milestone

Study Start

First participant enrolled

January 1, 2012

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2013

Completed
Last Updated

July 17, 2013

Status Verified

July 1, 2013

Enrollment Period

1.3 years

First QC Date

April 1, 2011

Last Update Submit

July 16, 2013

Conditions

Outcome Measures

Primary Outcomes (4)

  • assess the pacing system-, MRI- and implant procedure-related complication-free rate

    1 month

  • assess atrial and ventricular lead-related complication-free rate

    3 months

  • compare the changes in atrial and ventricular pacing thresholds before and after MRI, between MRI and control groups

    3 months

  • compare the changes in atrial and ventricular sense amplitude after MRI between MRI and control groups

    3 months

Secondary Outcomes (3)

  • Summarize all implant procedure, pacing system- and MRI procedure-related adverse events

    12 months

  • Summarize atrial and ventricular electrical performances

    3 months

  • Summarize atrial and ventricular lead handling

    2 weeks

Study Arms (2)

Control

ACTIVE COMPARATOR

Control

Procedure: control

MRI

EXPERIMENTAL

experimental

Procedure: MRI exam

Interventions

MRI examPROCEDURE

MRI exam

MRI
controlPROCEDURE

waiting room

Control

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who are candidates for dual-chamber pacemaker primo-implantation
  • Patients who have indication for implantation of a dual-chamber pacemaker according to the American College of Cardiology and the American Heart Association
  • Patients who are able and willing to undergo elective MRI scanning
  • Patients who are scheduled for implant of a Reply DR pacemaker and Filtrea lead(s) only
  • Patients who provided signed and dated informed consent

You may not qualify if:

  • Non MR-compatible device or material implant
  • Chronic atrial fibrillation (for atrial lead evaluation)
  • Incessant ventricular tachyarrhythmia (for ventricular lead evaluation)
  • Inability to understand the purpose of the study or refusal to co-operate
  • Unavailability for scheduled follow-ups at the implanting centre
  • Already included in another clinical study that could affect the results of this study
  • Inability or refusal to provide informed consent
  • Patient is minor (less than 18-year old)
  • Patient is pregnant (women of childbearing potential should have a negative pregnancy test prior to enrolment);
  • Patient has life expectancy of less than 1 year
  • Patient is forfeiture of freedom or under guardianship
  • Any patient to whom a contra-indication from device and lead labeling applies

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Francisco LEYVA, Dr

    Queen Elizabeth BIRMINGHAM UNITED KINGDOM

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 1, 2011

First Posted

April 25, 2011

Study Start

January 1, 2012

Primary Completion

May 1, 2013

Study Completion

May 1, 2013

Last Updated

July 17, 2013

Record last verified: 2013-07